Patient Satisfaction with Fentanyl Pectin Nasal Spray in Breakthrough Cancer Pain Management During Radiotherapy for Head and Neck Cancer

References

• Burton AW, Fanciullo GJ, Beasley RD, Fisch MJ. Chronic pain in the cancer survivor: a new frontier. Pain Med. 2007;8(2):189–198. doi:10.1111/j.1526-4637.2006.00220.x
   PubMed Web of Science ®Google Scholar
• Fallon M, Giusti R, Aielli F, et al. Management of cancer pain in adult patients: ESMO clinical practice guidelines†. Ann Oncol. 2018;29(Supplement_4):iv166–iv191. doi:10.1093/annonc/mdy152
   Web of Science ®Google Scholar
• Davies AN, Dickman A, Reid C, Stevens A-M, Zeppetella G. science committee of the association for palliative medicine of Great Britain and Ireland. The management of cancer-related breakthrough pain: recommendations of a task group of the science committee of the association for palliative medicine of Great Britain and Ireland. Eur J Pain. 2009;13(4):331–338. doi:10.1016/j.ejpain.2008.06.014
   PubMed Web of Science ®Google Scholar
• Mercadante S, Radbruch L, Caraceni A, et al. Episodic (breakthrough) pain: consensus conference of an expert working group of the European association for palliative care. Cancer. 2002;94(3):832–839. doi:10.1002/cncr.10249
   PubMed Web of Science ®Google Scholar
• Davies AN, Dickman A, Farquhar-Smith P, Webber K, Zeppetella J. incorrect use of the english language term “episodic.”. J Pain Symptom Manage. 2016;52(5):e1. doi:10.1016/j.jpainsymman.2016.06.002
   Web of Science ®Google Scholar
• Deandrea S, Corli O, Consonni D, Villani W, Greco MT, Apolone G. Prevalence of breakthrough cancer pain: A systematic review and a pooled analysis of published literature. J Pain Symptom Manage. 2014;47:57–76. doi:10.1016/j.jpainsymman.2013.02.015
   PubMed Web of Science ®Google Scholar
• Breivik H, Cherny N, Collett B, et al. Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann Oncol. 2009;20:1420–1433. doi:10.1093/annonc/mdp001
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Bruns D, Shoemaker B, Shoemaker SA. Breakthrough pain in community-dwelling patients with cancer pain and noncancer pain, part 1: prevalence and characteristics. J Opioid Manag. 6(2):97–108. doi:10.5055/jom.2010.0009
   Google Scholar
• CI RIPAMONTI, BAREGGI C. Pharmacology of opioid analgesia: clinical principles. In: Bruera ED, Portenoy RK, editors. Cancer Pain. Cambridge: Cambridge University Press; 2009:195–229. doi:10.1017/CBO9780511642357.012
   Google Scholar
• Caraceni A, Davies A, Poulain P, Cortés-Funes H, Panchal SJ, Fanelli G. Guidelines for the management of breakthrough pain in patients with cancer. J Natl Compr Canc Netw. 2013;11(Suppl 1):S29–36. doi:10.6004/jnccn.2013.0211.
   PubMed Web of Science ®Google Scholar
• HAS. Les médicaments des accès douloureux paroxystiques du cancer; 2014. Available from: http://www.has-sante.fr/portail/jcms/c_952643/les-medicaments-des-acces-douloureux-paroxystique. Accessed November 12, 2019.
   Google Scholar
• Zeppetella G, O’Doherty CA, Collins S. Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage. 2000;20(2):87–92. doi:10.1016/S0885-3924(00)00161-5.
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Burton AW, Gabrail N, Taylor D. A multicenter, placebo-controlled, double-blind, multiple-crossover study of fentanyl pectin nasal spray (FPNS) in the treatment of breakthrough cancer pain. Pain. 2010;151:617–624. doi:10.1016/j.pain.2010.07.028
   PubMed Web of Science ®Google Scholar
• Coluzzi PH, Schwartzberg L, Conroy JD, et al. Breakthrough cancer pain: A randomized trial comparing oral transmucosal fentanyl citrate (OTFC®) and morphine sulfate immediate release (MSIR®). Pain. 2001;91:123–130. doi:10.1016/S0304-3959(00)00427-9
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents; January 2019. Available from: https://apps.who.int/iris/bitstream/handle/10665/279700/9789241550390-eng.pdf?ua=1. Accessed May 8, 2020.
   Google Scholar
• Davies A, Sitte T, Elsner F, et al. Consistency of efficacy, patient acceptability, and nasal tolerability of fentanyl pectin nasal spray compared with immediate-release morphine sulfate in breakthrough cancer pain. J Pain Symptom Manage. 2011;41:358–366. doi:10.1016/j.jpainsymman.2010.11.004
   PubMed Web of Science ®Google Scholar
• Fisher A, Watling M, Smith A, Knight A. Pharmacokinetic comparisons of three nasal fentanyl formulations; pectin, chitosan and chitosan-poloxamer 188. Int J Clin Pharmacol Ther. 2010;48:138–145. doi:10.5414/CPP48138
   PubMed Web of Science ®Google Scholar
• Van Den Beuken-van Everdingen MHJ, De Rijke JM, Kessels AG, Schouten HC, Van Kleef M, Patijn J. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol. 2007;18:1437–1449. doi:10.1093/annonc/mdm056
   PubMed Web of Science ®Google Scholar
• Bhatnagar S, Upadhyay S, Mishra S. Prevalence and characteristics of breakthrough pain in patients with head and neck cancer: a cross-sectional study. J Palliat Med. 2010;13:291–295. doi:10.1089/jpm.2009.0266
   Web of Science ®Google Scholar
• Prieto I, Pardo J, Perez-Casas A, Olivera J, Luna J, Vara J. Fentanyl pectin nasal citrate (FPNC) to control breakthrough pain (BP) and improve dysphagia in head-and-neck cancer patients receiving radiation therapy (RT). Int J Radiat Oncol. 2012;84:S517. doi:10.1016/j.ijrobp.2012.07.1378
   Web of Science ®Google Scholar
• European Medicines Agency. PecFent. Summary of Product Characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/pecfent-epar-product-information_en.pdf. Accessed November 12, 2019.
   Google Scholar
• ADELF. Recommendations for professional standards and good epidemiological practices (version France 2007). Available from: http://adelf.isped.u-bordeaux2.fr/Portals/0/DOCUMENTATION/Recommandations_Version_Anglais-Janv.2008.pdf. Accessed November 12, 201.
   Google Scholar
• Cleeland CS, Ryan KM. Pain assessment: global use of the brief pain inventory. Ann Acad Med Singapore. 1994.
   Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, et al. The European organization for research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–376. doi:10.1093/jnci/85.5.365
   PubMed Web of Science ®Google Scholar
• Taylor D, Galan V, Weinstein SM, Reyes E, Pupo-Araya AR, Rauck R. Fentanyl pectin nasal spray in breakthrough cancer pain. J Support Oncol. 2010.
   Google Scholar
• Czernichow P, Chaperon J, Le Coutour X. Enquêtes descriptives PAR sondages In: Epidémiologie. Connaissances et pratiques [Epidemiology. Knowledge and practices]. Paris: Masson; 2001:84.
   Google Scholar
• Castile J, Cheng YH, Simmons B, Perelman M, Smith A, Watts P. Development of in vitro models to demonstrate the ability of PecSys®, an in situ nasal gelling technology, to reduce nasal run-off and drip. Drug Dev Ind Pharm. 2013;39:816–824. doi:10.3109/03639045.2012.707210
   PubMed Web of Science ®Google Scholar
• Ueberall MA, Lorenzl S, Lux EA, Voltz R, Perelman M. Efficacy, safety, and tolerability of fentanyl pectin nasal spray in patients with breakthrough cancer pain. J Pain Res. 2016;9:571–585. doi:10.2147/JPR.S106177
   PubMed Web of Science ®Google Scholar